

News Release

Nippon Chemiphar Co., Ltd.

March 5, 2020

Fair Trade Commission makes an Announcement concerning the Sale of Calvan

On this day, the Fair Trade Commission announced that it issued a cease-and-desist order and an order for payment of surcharge to another pharmaceutical company marketing hypertension therapeutic drug Calvan based on stipulations in the Antimonopoly Law.

In 2018, Nippon Chemiphar Co., Ltd. applied for leniency under the leniency system added to Japan's Antimonopoly Law in connection with its sales of lanthanum carbonate oral dispersing tablets and conducted an internal investigation into past actions that uncovered illegal conduct with regard to Calvan.

We voluntarily reported this fact to the Fair Trade Commission and made another application for leniency and have since consistently cooperated with the Commission's investigations.

Nippon Chemiphar has not received a cease-and-desist order or an order for payment of surcharge from the Fair Trade Commission in connection with either this situation, or the matter concerning lanthanum carbonate oral dispersing tablets.

However, Nippon Chemiphar regrets that it was involved in illegal conduct and sincerely apologizes to patients, business partners, shareholders, and all other stakeholders for any concerns or inconveniences this conduct may have caused.

The Group is working to thoroughly implement the recurrence prevention measures it announced on June 7, 2019 and is complying with laws and ordinances to ensure that a similar situation does not occur again in the future.

Moving forward, all of our executives and staff will sincerely strive to restore trust, strengthen compliance, and completely prevent recurrences.